Home > Search Results

Results: 1 to 20 of 25

Ezetimibe for hypercholesterolaemia: Executive summary of final report A10-02, Version 1.0

The aim of this investigation is the benefit assessment of treatment with ezetimibe (in mono- or combination therapy) compared to treatment with placebo or other lipid-lowering drugs, as well as to non-drug treatment options in patients with hypercholesterolaemia. The focus of the assessment was on patient-relevant outcomes.

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 18, 2011

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

To review the evidence for the clinical and cost-effectiveness of ezetimibe (in its licensed indication) as combination therapy or monotherapy for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia in the UK.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2008

Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease

This guideline updates for primary prevention, the NICE technology appraisal, ‘Statins for the prevention of cardiovascular events’ (TA94, 2007) and reviews and updates the recommendations made in the NICE guideline Lipid Modification (CG67, 2008) for primary and secondary prevention of cardiovascular disease (CVD). The scope for this guideline was limited to the identification and assessment of CVD risk and to the assessment and modification of lipids in people at risk of CVD, or people with known CVD. The guideline development group wishes to make clear that lipid modification should take place as part of a programme of risk reduction which also include attention to the management of all other known CVD risk factors.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: July 2014
Show search results within this document

Comparing Statins and Combination Drugs

How do statins and combination drugs compare in lowering "bad" cholesterol (LDL-c)?

PubMed Clinical Q&A [Internet] - National Center for Biotechnology Information (US).

Version: November 1, 2010

Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet]

In the United States, coronary heart disease and cardiovascular disease account for nearly 40% of all deaths each year. Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity among North Americans. In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.

Drug Class Reviews - Oregon Health & Science University.

Version: November 2009
Show search results within this document

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

This well-conducted review concluded that ezetimibe alone or in combination with a statin was effective in reducing low density lipoprotein cholesterol in short-term studies. When used alone, ezetimibe is less effective than statins. The authors' conclusions reflect the evidence and their recommendations for research appear appropriate given the lack of long-term data in the included studies.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis

This review concluded that the addition of ezetimibe to a statin was more effective in reducing low-density lipoprotein cholesterol and enabling more patients to achieve their goal, than doubling the dose of statin monotherapy, for the treatment of primary hypercholesterolaemia. These conclusions should be interpreted with caution due to the substantial variation observed for the pooled outcomes.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Stable Angina: Methods, Evidence & Guidance [Internet]

Angina is pain or constricting discomfort that typically occurs in the front of the chest (but may radiate to the neck, shoulders, jaw or arms) and is brought on by physical exertion or emotional stress. It is the main symptomatic manifestation of myocardial ischaemia and is usually caused by obstructive coronary artery disease restricting oxygen delivery to the cardiac myocytes. Other factors may exacerbate angina either by further restricting oxygen delivery (for example severe anaemia) or by increasing oxygen demand (for example left ventricular hypertrophy). Angina symptoms are associated with other cardiac disease such as aortic stenosis but the management of angina associated with non-coronary artery disease is outside the scope of this guideline.

NICE Clinical Guidelines - National Clinical Guidelines Centre (UK).

Version: July 2011

Depression in Adults with a Chronic Physical Health Problem: Treatment and Management

This clinical guideline was commissioned by NICE and developed by the National Collaborating Centre for Mental Health. It sets out clear, evidenceand consensus-based recommendations for healthcare staff on how to treat and manage depression in adults with a chronic physical health problem.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2010
Show search results within this document

Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care

This guideline has been developed to advise on supporting people with dementia and their carers in health and social care. The guideline recommendations have been developed by a multidisciplinary team of health and social care professionals, a person with dementia, carers and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to practitioners and service commissioners in providing and planning high-quality care for those with dementia while also emphasising the importance of the experience of care for people with dementia and carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2007
Show search results within this document

Lomitapide (Juxtapid) [Internet]

The objective of this review is to evaluate the beneficial and harmful effects of lomitapide added to other lipid-lowering therapy in patients with homozygous familial hypercholesterolemia (HoFH).

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: July 2015
Show search results within this document

Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia: A Systematic Review and Economic Evaluation

Familial hypercholesterolemia (FH) is an autosomal dominant genetic condition causing a high risk of coronary heart disease. The prevalence of this disease is about 1 in 500 in the UK, affecting about 120,000 people across the whole of the UK. Current guidelines recommend DNA testing, however, these guidelines are poorly implemented, therefore 102,000 or 85% of this group remain undiagnosed.

Health Technology Assessment - NIHR Journals Library.

Version: March 2012
Show search results within this document

Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy

This review concluded that there was insufficient evidence to support the benefit for mortality, myocardial infarction, stroke, and revascularisation procedures of statin combination therapy over high-dose monotherapy in high-risk patients needing intensive lipid-lowering therapy. The authors' conclusion reflected the evidence presented, but the reliability is potentially compromised by search restrictions and unclear quality of included studies.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Identification and Management of Familial Hypercholesterolaemia (FH) [Internet]

While the NHS in England and Wales has made spectacular progress in improving the secondary prevention of cardiovascular disease, we now need to work harder to identify those who are at particularly high risk of myocardial infarction.

NICE Clinical Guidelines - National Collaborating Centre for Primary Care (UK).

Version: August 2008
Show search results within this document

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]

Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism characterized by highly elevated total cholesterol (TC) concentrations early in life, independent of environmental influences. Around 1 in 200 to 1 in 500 persons in North America and Europe are estimated to have heterozygous FH. When untreated, FH is associated with a high incidence of premature clinical atherosclerotic cardiovascular disease.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: August 2016
Show search results within this document

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.

National Academies Press (US).

Version: 2010
Show search results within this document

Chronic Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care

The Renal National Service Framework (NSF), and the subsequent NICE Clinical Practice Guideline for early identification and management of adults with chronic kidney disease (CKD) in primary and secondary care (CG73), served to emphasise the change in focus in renal medicine from treatment of established kidney disease to earlier identification and prevention of kidney disease.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: July 2014
Show search results within this document

Lower Limb Peripheral Arterial Disease: Diagnosis and Management [Internet]

Lower limb peripheral arterial disease (known in the document as peripheral arterial disease, PAD) is a marker for an increased risk of potentially preventable cardiovascular events even when it is asymptomatic. If it becomes symptomatic it can lead to significant impairment of quality of life through limiting mobility and in its more severe manifestations may lead to severe pain, ulceration and gangrene and is the largest single cause of lower limb amputation in the UK.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: August 2012

Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk

Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health.

National Academies Press (US).

Version: April 20, 2015
Show search results within this document

Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]

For purposes of this report, multifactorial dyslipidemia refers to dyslipidemias involving elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) that are not familial hypercholesterolemia (FH). There is evidence that elevated TC and LDL-C concentrations in childhood, and especially adolescence, are associated with markers of atherosclerosis in young adults.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: August 2016

Systematic Reviews in PubMed

See all (36)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...